8:55 am Chair’s Opening Remarks

Reinventing Manufacturing Capabilities to Equip the Field Prior to Rapid Growth

9:00 am Designing TCR Manufacturing Networks for Scalability


• Establishing scalable manufacturing processes
• Utilizing automated technologies to enable reliable throughput
• Designing end-to-end value chains to deliver high volumes of products

Selecting the Optimal Target Antigen to Create an Effective TCR Therapy

9:30 am Expanding Patient Coverage for TCR-T Therapies by Broadening HLA Type Targeting


• Application of TargetScan discovery platform to diverse HLA types for novel target epitope identification
• Using ReceptorScan to identify lead TCRs for novel HLA epitopes
• Leveraging proprietary human proteome libraries across diverse HLAs to assess potential off-target safety risks for TCRs

10:00 am Creating Effective and Safe TAC T Cell Therapies by Targeting Compartmentalized Surface Antigens in Solid Tumors


• The TAC receptor co-opts the endogenous TCR for efficacious and safe T cell anti-tumor responses without MHC restriction
• Compartmentalized surface antigens add to the repertoire of novel tumor-selective targets
• Development status of TAC T cell products in the treatment of solid tumors

10:30 am Morning Refreshment Break & Networking

Investigating Methods to Increase TCR Efficacy

11:30 am The Novel Platform of Discovery and Engineering TCR Mimic Antibodies to Enhance Therapeutic Index of Efficacy and Safety

  • Dongxing Zha CTO, TCR Discovery & Engineering, Alloy Therapeutics


• Examining methods to engineer TCR mimic antibodies to magnify specificity for target antigens
• Reviewing the pros and cons of affinity enhanced TCR mimic antibodies to safeguard patient safety
• Escalating affinity to the target peptide as well as the MHC to optimize efficacy

12:00 pm Acknowledging the Advantages of a TCR Bispecific Antibody System

  • Cheng Liu Founder & CEO, Eureka Therapeutics


• Creating effective TCR antibodies to expand the target pool
• Adopting an antibody TCR technique to ease manufacturing processes
• Valuing the lack of HLA restrictions with TCR antibody use to reduce off-target toxicities

12:30 pm Lunch Break and Networking

1:30 pm Targeting Solid Tumors Using Neoantigen-Specific TCR-T Cells

  • Drew Deniger VP, Research & Development , Alaunos Therapeutics


• Ziopharm’s proprietary neoantigen-reactive TCR discovery platform
• Translation of TCR-T cells to the clinic for the treatment of solid tumors
• Next generation TCR-T cells co-expressing membrane-bound interleukin-15

Navigating Preclinical & Clinical Hurdles to Advance TCR Therapy Development

2:00 pm Developing Preclinical Models that Effectively Evaluate Safety and Efficacy of TCR-T Cell Therapy

  • Sungeun Kim Principal Scientist, Oncology Research, Amgen


• Assessing cross-reactivity and safety through extensive in vitro assays
• Evaluating efficacy and PD in humanized mouse models

2:30 pm Afternoon Refreshments and Networking

3:00 pm Roundtable: Building Awareness of TCR Therapies to Promote Study Enrolment

  • Piotr Pierog VP, Precision & Translational Medicine, Affini-T Therapeutics


• Educating the field on the potency of TCR therapies to increase physician referral
• Promoting these therapies and their clinical trials to aid patient enrolment
• Brainstorming effective methods to spread the word of TCR therapies, especially during the Covid-19 pandemic

3:30 pm HuTCR: a Next-Generation TCR and Epitope Discovery Platform to Design TCR-T Therapies of High Efficacy and Safety


• HuTCR mouse lines carrying human TCRs and multiple HLAs to avoid central tolerance and identify TCRs of high affinity and specificity
• Unbiased in vivo epitope discovery engine to identify naturally processed epitopes across multiple HLA types
• TK-8001, a MAGE-A1 targeting TCR-T therapy for solid tumors

4:00 pm Close of Conference Day Two